R. Donald Harvey
0000-0002-4217-1313
156 papers found
Refreshing results…
Drug-drug Interaction (ddi) Study Between The Investigational Nae Inhibitor Pevonedistat (tak-924) And Fluconazole Or Itraconazole In Patients With Advanced Solid Tumors.: pii-084
Navigating the Landscape of Molecular Testing and Targeted Treatment of Non--Small Cell Lung Cancer
A Phase I Study To Assess Food Effect On Oprozomib In Patients With Advanced Malignancies.: pii-090
Precision, accuracy, and resolution—Dose selection of oral anticancer agents
Relationship of Carfilzomib Dosing and Duration of Therapy (DOT) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis
Abstract B26: Phase 1b trial of investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in combination with docetaxel, paclitaxel/carboplatin, or gemcitabine in patients (pts) with solid tumors
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes
Safety Profile of Oral Ixazomib: Experience from 761 Patients (Pts) Across 14 Phase 1 or Phase 1/2 Clinical Studies
Abstract CT303: A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors
Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer
Plerixafor in combination with granulocyte--colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial
population Pharmacokinetic And Pharmacodynamic Analysis Of Vorinostat In Patients With Advanced Solid Tumors With Varying Degrees Of Hepatic Function: pii-029
A Phase 1 Study of the Pharmacokinetics (PK) and Safety of Pomalidomide+ Low Dose Dexamethasone (POM+ LODEX) in Patients (PTS) With Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI)
POMALIDOMIDE Plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: PHASE 1 PHARMACOKINETICS AND SAFETY
novel immunotherapeutics and cytochrome P450.: 92.
Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial
Real-World Practice Patterns with Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma
Missing publications? Search for publications with a matching author name.